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The currently developed and validated in vitro tests for female and male fertility and also for
developmental toxicity are described and evaluated according to their potential use as screening
or replacement alternatives to the established in vivo tests in reproductive and developmental
toxicology. Alternative methods today can only be used to evaluate a few specific components of
the integrated reproductive functions in both females and males. However, in the field of
developmental toxicity testing there is a strong theoretical and empirical basis for the predictive
power of in vitro screens using mammalian embryos as well as embryonic cells and tissues.
Several of these assays have been validated or are currently undergoing validation in several
laboratories and are >80% concordant with in vivo results. Failure to achieve 100% accuracy
reflects the inherent limitations of these systems, which are manageable, as the concordance
rates are still good. The level of concordance suggests that these assays are adequate for
screening purposes to complement traditional in vivotesting. The use of these assays as screens
will save valuable in vivo testing resources for those compounds most likely to enter the market
and to which people will be exposed. - Environ Health Perspect 106(Suppl 2):571-576 (1998).
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Introduction
Reproduction is a continuous cycle. For the conducting mechanistic reproductive
purposes oftoxicity testing, however, it is toxicity studies. Additionally, in vitro meth-
broadly divided into pregnancy in females, ods already play a valuable role in so-called
including prenatal or postnatal develop- secondary testing, i.e., in the screening of
mental toxicity, and the remainder ofthe series ofstructurally related chemicals when
cycle in both males and females during at least one of the chemicals is ofknown
which fertility maybe impaired. reproductive toxicity in vivo.
During the past 20 years research in The majority ofresearch into the devel-
reproductive toxicology has focused on opment ofalternative tests has concentrated
the use of alternatives to living mammals on teratogenicity, which is only one mani-
for testing the potential reproductive toxi- festation ofadverse effects on development
cities of chemical and physical agents. and does not cover fertility, which includes
Recent reviews include an Organisation for sexual behavior, spermatogenesis, oogenesis,
Economic Co-operation and Development fertilization and the development of the
workshop in Ottawa, Canada, in 1992 (1) zygote up to term, postnatal development,
and aEuropean Centre for theValidation of and hormonal activity.
Alternative Methods (ECVAM) workshop InVivoTesting for
in Ispra, Italy, in 1994 (2). International IngVivo Purpor experts concluded at both conferences Regulatory Purposes
that the use of in vitro methods is well Currently, reproduction/development
established and that they are invaluable for screening tests (3,4) or multigeneration
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studies must be conducted to provide
information on the effects of industrial
chemicals on all aspects ofthe highly com-
plex reproductive cycle (5,6). For chemi-
cals used as drugs, segment studies must be
conducted covering three important phases
ofpre- and postnatal development and fer-
tility (7). Because ofthe complexity ofthe
reproductive cycle, from gamete matura-
tion through implantation of the early
embryo into the uterus, and because ofthe
lack ofvalidated alternative tests for most
steps in the cycle, testing in living animals
is the only option currently available for
assessing the possible effects of chemicals
on reproduction. Moreover, because of
the complexity offunctions that are only
found in living animals, in vitro screening
may never be able to cover all of the
aspects offertility. Thus, the key question
is whether sufficient information can be
derived from alternative tests to be able to




Some aspects of female reproductive
function can be modeled in vitro, and sev-
eral cellular components of the female
reproductive organs can be maintained in
culture (8). Although none of the organs
have been used or validated as toxicity
screens, several may be useful for specialized
toxicologic studies. In the future, a battery
ofsuch systems may be able to cover a large
proportion ofthe female reproductive cycle.
In females, the proliferation of
primordial germ cells and the initial
steps of meiosis occur long before birth.
From puberty onward, a small number of
the primary oocytes complete oogenesis
and are released from the ovary. Ovarian
somatic cells (granulosa, thecal, and stro-
mal cells) can be maintained in culture (8)
and any adverse effects can be assessed by
examining cell morphology, viability, and
hormonal responsiveness.
Techniques for in vitro fertilization
(including functional maturation ofsper-
matozoa) are routine, both clinically and in
farm and laboratory animals. The methods
used have not been validated for testing
purposes, although some toxicologic studies
have been performed (9). For example, the
mammalian preimplantation period can be
investigated by culturing embryos from the
first cleavage divisions up to implantation,
Environmental Health Perspectives * Vol 106, Supplement 2 - April 1998 571H. SPIELMANN
and toxicologic investigations at the
chromosomal level have been published
(10). Thus, there are no alternative tests
available in the near future that would
enable the screening ofchemicals for female
reproductive toxicity with the predictivity
required for the safety assessment ofchemi-
cals. In the long term, a complex battery of
in vitrotests may be devised.
MaleFertility
There is particular interest in the
development ofalternative approaches for
assessing male reproductive toxicity. The
human male has a relatively low sperm
count; the number ofsperm per ejaculate is
typically only between 2- and 4-fold higher
than that at which fertility is significantly
impaired. In contrast, the number ofsperm
in a rat or rabbit ejaculate is many times (up
to 1000-fold) that which will produce max-
imum fertility. Epididymal sperm count can
be reduced by as much as 90% in the rat
without significantly affecting fertility.
Consequently, animal models maybe insen-
sitive indicators ofhuman reproductive
hazards. Studies on male reproductive
toxicity are aided by the readyavailability of
human target cells.
The production ofspermatozoa from
stem cells is a complex process that takes
about 5 weeks in mice and 11 weeks in
humans. Chemicals can disturb normal
spermatogenesis by direct interaction with
targets within the testis itself, or indirectly
by interfering with hormonal stimulation
or alterations in blood supply.
It is not possible to mimic the whole of
the male reproductive cycle in vitro, but sev-
eral components can be studied individually.
Although they have been used extensively in
toxicologic studies, theystill do not represent
a viable alternative to in vivo tests. Male
germ cells are produced from stem cells
throughout mature life. Thus, it should be
easier to devise culture systems that are able
to support thewholeofspermatogenesis.
Several testicular cell types can be
maintained in culture, either alone or in
combination; these include Sertoli-germ
cell cocultures, Sertoli cell-enriched cul-
tures, germ cell-enriched cultures, Leydig
cell cultures, and Leydig-Sertoli cell cocul-
tures. All ofthese systems have been used
successfully to studyspecific features oftes-
ticular toxicity (11). Primary cultures of
testicular cells retain many ofthe in vivo
characteristics but only have a limited life
span. The ability to study individual cell
populations from a heterogeneous organ
such as the testis is a powerful tool for
probing mechanisms oftoxicity. However,
the loss of interactions with other cell
types is a serious limitation to their use for
screening purposes.
Additional measurements may be
incorporated into current in vivo testing
protocols. High quality histopathology of
the testes and epididymis would enable
effects on specific cell populations to be
evaluated. Alternatively, recently developed
flow cytometric techniques could be used.
One ofthe flow cytometric methods devel-
oped for detecting alterations in spermato-
genesis allows simultaneous measurement
of cellular DNA content, RNA content,
and stainability (12). This procedure pro-
vides a rapid assessment of up to eight
different testicular cell populations.
SemenAnalyses
There are several techniques available for
monitoring sperm motility, morphology,
andvarious other aspects ofsemen composi-
tion, including the fertilizing ability of
sperm. Such approaches could be used for
both human and animal semen analyses.
The direct addition of test chemicals to
semen samples in vitro may be a valuable
approach, given the availability ofhuman
material. Fertilizing capacity declines
with increasing proportions of abnormal
sperm head morphology, and there is ahigh
correlation between chemical-induced
sperm head abnormalities and altered sperm
chromatin structure in the mouse (13).
Developmental Toxicity:
In VitroTests
Over the past 20 years, more than 30
different culture systems have been pro-
posed as tests for developmental toxicity.
The majority ofthese tests have each been
used by only one laboratory. The culture
systems fall into four categories: established
cell lines, primary cell cultures, nonmam-




Established cell lines that have been used for
developmental toxicity screening include
human embryonic palate mesenchymal
(HEPM) cells (14), mouse ovarian tumor
(MOT) cells (15), and neuroblastoma cells
(16). The results of a blind trial with a
dual HEPM/MOT approach showed an
unacceptably high level offalse positives
(>50%) (17).
In a more recently developed approach,
blastocyst-derived totipotent embryonic
stem (ES) cell lines ofthe mouse were used
for in vitro embryotoxicity testing. ES cells
can be maintained in an undifferentiated
state in the presence offeeder layers and/or
purified leukemia inhibitory factor (LIF).
When the LIF is removed, ES cells differen-
tiate into a variety ofcell types depending
on the culture conditions. For example, in
the mouse, muscle cell differentiation from
ES cells reflects myogenesis in vivo (18),
and the development ofhemopoietic cells
parallels hematopoiesis in the developing
embryo (19).
ES cells offer several new approaches
with respect to screening for embryotoxic-
ity in vitro, enabling the use ofdifferentiat-
ingpermanentembryonic cells. Cytotoxicity
(20) and effects on differentiation (19,21)
have been used as end points in embryotox-
icity tests with ES cells; inhibition ofthe
differentiation ofES cells in a micromass
culture has proved a particularly promising
assay under routine testing conditions (21).
Determination ofthe two essential features
of embryotoxic agents (i.e., inhibition of
differentiation combined with a higher
sensitivity of embryonic cells than adult
tissues to cytotoxic damage) in a single
assay procedure with ES cells was recently
attempted (22). The predictive value of
this embryonic stem cell test (EST) was as
good as the results obtained with in vitro
embryotoxicity tests using either rodent
whole embryos or embryonic tissues.
ES cells are routinely used in the
production oftransgenic mice, and methods
to introduce targeted mutations and
reporter constructs are well established.
Transgenic markers could be devised to sim-
plify the end points used in aparticular toxi-
city test and to enable the automation of
suchassays. ECVAM supports the continued
development ofthese approaches.
AggregateandMicromass Cultures
Aggregates ofprimary cultures of chick
embryo neural retina cells (CERC) provided
encouraging results as a screen for develop-
mental toxicity (23). The CERC assay may
not have gained wider acceptance because it
is based on the differentiation ofnonmam-
malian cells from an organ that is not the
primary target ofembryotoxic agents in the
human embryo.
When cells from the undifferentiated
mesenchyme ofearly chick embryo limbs
were cultured in small volumes at high den-
sity, they formed numerous small foci of
differentiating chondrocytes within a back-
ground ofapparently undifferentiated cells.
Cell adhesion, movement, communication,
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division, and differentiation all occur in
micromass cultures (24). In principle,
the micromass test is based on detecting
the ability of a particular chemical to
inhibit the formation of foci. Embryonic
limb or central nervous system (CNS)
cells (usually midbrain, which form foci of
neurons) from chick, mouse, or rat can be
used (25,26). The technique has subse-
quently been modified for use with 96-well
microtiter plates (27). Cells can be exposed
either directly in culture or transplacentally
prior to culture (28).
Several structure-activity studies have
shown that the micromass test can distin-
guish between teratogens and nonterato-
gens within a particular chemical class, e.g.,
retinoids (28) and triazole antifungal drugs
(29). In some cases, organ-, species-, and
strain-specific toxicity have been modeled
in micromass cultures. For example, ethyl-
enethiourea is more toxic to midbrain than
to limb cultures (30) and is more toxic to
the rat CNS than to the mouse CNS (31).
Differentiating cells in both midbrain
and limb cultures express cytochrome P450
isozymes (32) and, at least in the case of
limb cells, these are able to metabolize
chemicals such as phenytoin and cyclo-
phosphamide to their toxic metabolites.
Validation studies using chemicals from a
variety ofclasses indicate that the percentage
ofteratogens detected with micromass cul-
tures mayvary between approximately 60 to
90%, and that the percentage ofnonterato-
gens identified correctly may vary between
89 and 100% (26,27,33). It is possible that
much ofthis variation is accounted for by
differences in the exact methodology used,
and none ofthese studies are considered
definitive.
Thus, micromass cultures represent
robust test systems for studying potential
teratogens. It was recommended that the
micromass method be included in a com-
parative trial to determine its applicability
relative to several other available in vitro
systems (2).
Embryos ofLowerOrderSpedes
Numerous tests that use embryos of
submammalian vertebrate and invertebrate
species for detecting the teratogenic poten-
tials ofchemicals have been described. The
organisms that have been used include
hydra, fish, frogs, crickets, Drosophila, brine
shrimp, and slime mold. Several ofthese
are currently being used extensively as
models for investigating mechanisms of
development. Because any stage or compo-
nent ofdevelopment is a potential target
for toxicants, the existence ofspecies differ-
ences is a strong argument in favor ofusing
vertebrate models for predictive screening.
However, subvertebrate systems may have
applications inecotoxicologic monitoring.
Of the nonavian vertebrate systems
available, only the frog embryo teratogene-
sis assay Xenopus (FETAX) has undergone
limited validation using about 40 different
substances (34). The overall accuracy in
predicting teratogenic potential has been
claimed to be 79 to 83% (34). FETAX is
low cost and rapid and uses a species com-
monly maintained under laboratory condi-
tions. The assay is limited by the aqueous
solubility of test substances, the relative
lack ofvalidation, and the small number
oflaboratories that have used the system.
Nevertheless, it has been recommended
that FETAX be induded in a comparative
trial ofalternative tests for developmental
toxicity (1,2).
AvianEmbryos
Although avian embryos are widely used as
models in developmental biology, they
have rarely been used for embryotoxicity
testing. The chick embryotoxicity screen-
ing test (CHEST) was devised by Jelinek
and co-workers (35) and has been used
extensively in their laboratory, but not else-
where. Intraamniotic injection eliminates
the problem ofcontinuous exposure ofthe
embryo because the test substance is readily
distributed to the extraembryonic compart-
ments. Growth retardation, malformation,
and death as well as dose-response and
stage-response relationships and malfor-
mation spectra are easily determined. The
results obtained from testing over 130 com-
pounds have been published (35,36). One
general problem with CHEST has been the
inability to distinguish general toxicity
from specific developmental effects.
MammalianWhole
Embryo Culture
Mammalian embryos can be maintained in
culture for short periods throughout the
phase from fertilization to the end of
organogenesis (10). For toxicity testing,
the period from the end ofgastrulation to
midorganogenesis has been investigated
extensively. Screening systems using mouse
(37) and rat (38) embryos have been pro-
posed, and the culture of rabbit embryos
has recently been optimized (39).
Head fold or early somite stage embryos
are dissected free from maternal tissue,
parietal yolk sac, and Reichert's mem-
brane, leaving the visceral yolk sac and
ectoplacental cone intact. The conceptus is
cultured in medium under defined gassing
conditions for 24 to 48 hr, usually in a
roller bottle system. Avariety ofmedia have
been used, all ofwhich contain a high pro-
portion ofserum. Rat serum is most com-
mon (40), but mouse, rabbit, cow, monkey,
and human sera (41) have been used. The
test compound can be added to the cultures
for defined periods or for the entire culture
period. Metabolic activation systems can be
incorporated, including the addition of
S9 or microsomal fractions ofliver from
different species, coculture with hepato-
cytes, sequential hepatocyte/whole embryo
culture, and the addition ofserum from
treated animals orhumans (42).
At the end of the culture period a
number of end points can be measured,
including effects on the development ofthe
visceral yolk sac vascularization and circu-
lation; effects on hematopoiesis, embryonic
growth (e.g., size and protein and DNA
contents); and differentiation (number of
somites, morphologic score); and dysmor-
phogenic effects (37,38,43). Interpretation
of the results takes into account adverse
effects on yolk sac development and
embryonic growth and differentiation as
well as adverse effects specifically on dys-
morphogenesis. Validation studies have
been carried out (43) and an interlabora-
tory validation study has been conducted
(44). In avalidation study on different cul-
ture systems, six pairs ofcoded compounds
were tested in chick and rat embryo cul-
tures and in brain cell aggregate cultures
(45). Bechter et al. (46) reported an excel-
lent agreement between in vivoand in vitro
data for a series ofretinoids.
Mammalian whole embryo culture
systems are well developed in vitro tests for
the detection ofpotentially teratogenic
compounds and for the elucidation of
mechanisms ofteratogenicity. This in vitro
system has been used in many academic
and industrial laboratories and has proved
to be a valuable tool. It allows the detec-
tion ofdysmorphogenesis in many organs
and the comparison ofspecific dysmor-
phogenic effects with general adverse
effects on growth and differentiation. In
addition, it enables the potencies ofstruc-
turally related compounds to be ranked.
Concentrations of test compounds and
metabolites can easily be monitored in the
culture medium and embryonic tissues.
However, the system has clear limita-
tions: it is relatively complex, covers only a
part oforganogenesis, and requires high
technical skills. The test can be costly and
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it uses mammalian tissue and serum.
Whether this is justified with respect to
its use as a screen may be evaluated by




The production ofa direct effect on the
developing organism depends on the con-
centration/time relationship ofthe chemical
and/or its active metabolite(s) in the target
cells. Therefore, toxicokinetic and metabo-
lism studies are ofcrucial importance for the
design and interpretation ofdevelopmental
toxicity studies with both in vitro and in
vivo methods (47,48). In vivo target con-
centrations are dependent on maternal
absorption ofthe compound, its distribu-
tion, metabolism, and excretion, and its pla-
cental transferanddistribution intheembryo.
Toxicokinetic studies are also important in
vitro. The presence ofthe compound and its
stability in the culture medium must be veri-
fied, along with an assessment ofits trans-
port to, and uptake by, the tissues and cells
in culture, its metabolic activation, and its
cellular distribution.
Toxicokinetic studies are essential for
interpreting results obtained in vitro and
for extrapolating these to the in vivo situ-
ation. Activities of added metabolizing
systems, such as liver homogenate frac-
tions, isolated enzymes, and hepatocytes,
can be assessed by analytical techniques.
Measurement ofthe compound in the cul-
tured tissues and cells is critical, so the tar-
get concentration needed to yield an effect
can be determined. Such measurements are
especially important iflittle or no activity
is observed in vitro so that false negatives
can be excluded.
Toxicokinetic parameters often differ
drastically between in vivo and in vitro sit-
uations. For example, in vivo drug levels
can fluctuate markedly between doses
because of the short half-lives of many
chemicals, and high concentration peaks
alternate with low or negligible drug lev-
els. In contrast, the chemical is added in
vitro to the culture medium and may per-
sist for extended periods oftime unless it is
degraded by hydrolysis or enzymes present
in the culture medium.
Discussion
The current status of in vitro tests for
reproductive and developmental toxicity
testing is summarized in Table 1. It is obvi-
ous that for reproductive toxicity, alterna-
tive methods can only be used to evaluate a
Table 1. In vitrotests for reproductive and developmental toxicity.
Testsystem End point(s) Application Reference
Fertility, rodent and human tissues
Female
Ovarian cells: mouse, human Morphology, Mechanistic studies (8)
hormonal response
In vitrofertilization: mouse, human Differentiation Toxicologic studies (9)
Preimplantation embryos Differentiation Toxicologic studies (10)
Male
Testicular cells: mouse, human Morphology, Mechanistic studies (11,12)
differentiation Toxicologic studies (11)
Sperm: mouse, human Morphology, Mechanistic studies (13)
in vitrofertilization (13)
In vitrodevelopmental toxicity
Cell lines: rodent and human
Ovarytumor cellsa: mouse Attachment Toxicityscreening (15)
Palatal cellsa: human embryo Proliferation Toxicity screening (12)
Neuroblastoma: mouse Differentiation Toxicity screening (16)
Embryonic stem cellb: mouse Differentiation Toxicity screening (18-22)
Primary cells and organ cultures: chick and
rodenttissues
Embryonic retina: chick Aggregation culture Toxicity screening (23)
Brain aggregates: rat Aggregation culture Toxicity screening (45)
Neural tissueab: rat Differentiation, Toxicity screening (25,28,30)
micromass
Limb bud cellsbc: mouse, rat Differentiation, Toxicityscreening (26,30,31)
micromass
Whole embryo culture: lowerspecies
FETAXtesta: frog Differentiation Toxicity screening (34)
CHESTtesta: chick Differentiation Toxicity screening (35,36)
Chick embryos Differentiation Toxicity screening (45)
Whole embryo culture: mammalian
Preimplantation embryo: mouse, rat, rabbit Development Mechanistic studies (10)
Postimplantation embryo: mouse, rat, rabbit Differentiation Mechanistic studies (37-39)
Postimplantation embryobc: mouse, rat Differentiation Toxicityscreening (40-46)
aTest validated under blind conditions: results ambiguous. bUndergoing formal validation in an ECVAM project in
1997/1998. cTestvalidated under blind conditions: result positive.
few components ofintegrated reproductive
functions both in the female and the male.
Table 1 also shows that the situation is
more promising in the field of in vitro
embryotoxicity testing, as many tests can
be used for screening purposes and a few
have undergone interlaboratory validation
with coded chemicals. Some of the tests
using mammalian cells and embryos have
provided promising results and may be
used as screens to set priorities for in vivo
testing for regulatory purposes, e.g., the
ESTs, micromass cultures, and whole
embryo cultures. Therefore, ECVAM is
currently funding a combined prevalida-
tion and validation trial ofthe three latter
tests according to ECVAM's schemes for
the prevalidation and validation oftoxicity
tests (49,50).
One important limitation of the in
vitro screening tests in developmental
toxicity shown in Table 1 is that they
have been selected to detect structural
alterations but not any other potential
manifestations ofdevelopmental toxicity.
Therefore, one would not expect these
tests to predict decreased fetal weight or
mortality. Moreover, none of the tests
would predict functional abnormalities
induced by chemicals.
Therefore, even the best in vitro assays
are limited in their biology because ofthe
following facts: a) none of the tests repre-
sent the entire spectrum ofdevelopmental
events and embryotoxic mechanisms; b)
the metabolizing capacity of embryonic
cells, tissues, and organs is limited; and c)
the pharmacokinetic parameters in vitroare
not identical to the situation in vivo.
However, the limitations of in vitro
screens for embryotoxicity can be managed
by test selection and design. In vitrosystems
can include specific metabolizing systems or
be manipulated to approximate the phar-
macokinetic behavior ofthe test agent in
the species ofinterest. In fact, the ease with
which such test systems can be manipulated
may in some cases mean that limitations
can be turned into advantages.
The primary reason for the general bias
oftoxicologists against in vitro screens is
the unrealistic standards that they are
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expected to meet. Despite protests to the
contrary, it appears that the in vitro tests
are expected to be as predictive as, or more
predictive than, traditional in vivo screens.
In other words, they are expected to meet
the standards ofreplacement. For example,
it is usually anticipated that in vitro tests
are able to identify thalidomide as a terato-
gen despite the fact that thalidomide can-
not be identified when tested in vivo in the
most common rodent species.
Today in vitro assays for developmental
toxicants can be used for a number of
product development and industrial pur-
poses. The three major applications are as
follows (51): a) in the earliest stage of
product development, to select from among
a group ofcandidate compounds for a par-
ticular indication those compounds that
are the least likely to cause developmental
toxicity; b) to compare the developmental
toxicity potential ofa new chemical that is
only a slight modification of an existing
chemical that has already been tested in
vivo; and c) to evaluate compounds for
which testing is not routinely performed,
usually because the anticipated exposure is
very low.
Eventually in vivo screening will only
have to be conducted on compounds that
passed the initial in vitro screen. In the lat-
ter two instances it may not be necessary to
carry out anyadditional testing in vivo.
There are other applications of in vitro
screens that should be considered seriously.
The most significant potential application
would be to set priorities for definitive test-
ing of compounds that have been on the
market for many years and for which no
developmental toxicity data exist to date.
Among these untested existing chemicals,
in vitro screens would permit identifying
compounds that may have developmental
toxic potential. Using them will save time
and money, but they will not replace in
vivo testing for compounds to which peo-
ple may substantially be exposed. They
will, however, provide information on
developmental toxicity for entire classes of
compounds for which these data are never
routinely obtained. Therefore, using vali-
dated in vitro tests will increase flexibility
in product development and testing with-
out compromising safety. In vivo tests will
still be conducted on all new pharmaceuti-
cal agents and commercial chemicals for
which exposure is significant. However, the
in vitro tests will obviate the need to test in
vivo materials when there is a high likeli-
hood that their developmental toxicity
potential would prevent their introduction
into the market.
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